Related Experiment Video
Updated: Jul 8, 2026
A Protocol for Constructing a Rat Wound Model of Type 1 Diabetes
Published on: February 17, 2023
Harnessing HIF-1α for Diabetic Wound Healing: From Molecular Insights to Therapeutic Strategies
Esakkimuthukumar Mariappan1, Akey Krishna Swaroop1, Saranya Rajanbabu1
1Department of Pharmaceutical Chemistry, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Ooty, Tamilnadu, India.
Introduction:
Diabetes mellitus severely affects the wound healing process because high blood glucose levels impair insulin availability and increase insulin resistance. The major molecular pathways associated with diabetic wound healing, such as VEGF, Wnt/β-catenin, PI3K/AKT, TGF, MAPK, NF-kappa B, and Nrf2, are regulated by hypoxia-inducible factor-1α (HIF-1α). However, HIF- 1α is rapidly degraded through the ubiquitin-proteasome pathway, which limits its therapeutic potential.
Methods:
A systematic literature review was conducted using databases such as PubMed, Scopus, Web of Science, and Google Scholar. Relevant articles focusing on the regulation and degradation of HIF-1α, particularly through the Von Hippel-Lindau (VHL) protein and prolyl hydroxylase domain (PHD) enzymes, were selected to address the review objectives.
Results:
HIF-1α plays a crucial role in modulating inflammation, angiogenesis, and tissue repair during wound healing. Under normoxic conditions, HIF-1α is hydroxylated by PHD enzymes and subsequently recognized by VHL for degradation via the ubiquitin-proteasome pathway. Inhibition of VHL or PHD enzymes can be a potential target to stabilize HIF-1α, thereby promoting wound healing in diabetic preclinical models.
Discussion:
Targeted stabilization of HIF-1α through inhibition of its degradation pathway represents a promising therapeutic strategy. Several HIF-1α stabilizers currently in clinical trials for anemia and chronic kidney disease demonstrate the feasibility of this approach, although their application in diabetic wound healing requires further investigation.
Conclusion:
Regulation of HIF-1α degradation presents a novel and promising therapeutic approach for managing diabetic wounds. Future studies are needed to translate these findings into effective clinical therapies targeting HIF-1α stabilization in diabetic wound healing.
Insights
Stabilizing hypoxia-inducible factor-1α (HIF-1α) by inhibiting its degradation pathway shows promise for diabetic wound healing. This strategy targets key molecular pathways impaired by diabetes, offering a novel therapeutic avenue.
Area of Science:
- Biomedical Science
- Molecular Biology
- Wound Healing Research
Background:
- Diabetes mellitus significantly impairs wound healing due to hyperglycemia, affecting insulin signaling and increasing resistance.
- Key molecular pathways (VEGF, Wnt/β-catenin, PI3K/AKT, TGF, MAPK, NF-kappa B, Nrf2) crucial for diabetic wound healing are regulated by hypoxia-inducible factor-1α (HIF-1α).
- The therapeutic potential of HIF-1α is limited by its rapid degradation via the ubiquitin-proteasome pathway.
Purpose of the Study:
- To review the regulation and degradation mechanisms of HIF-1α in the context of diabetic wound healing.
- To explore the potential of targeting HIF-1α degradation pathways for therapeutic intervention in diabetic wounds.
Main Methods:
- A systematic literature review was performed using major scientific databases (PubMed, Scopus, Web of Science, Google Scholar).
- Articles were selected based on their focus on HIF-1α regulation, degradation (specifically involving Von Hippel-Lindau protein and prolyl hydroxylase domain enzymes), and relevance to wound healing.
Main Results:
- HIF-1α is essential for modulating inflammation, angiogenesis, and tissue repair during wound healing.
- Under normal oxygen conditions, HIF-1α is hydroxylated by prolyl hydroxylase domain (PHD) enzymes, leading to its recognition by the Von Hippel-Lindau (VHL) protein and subsequent degradation.
- Inhibiting VHL or PHD enzymes can stabilize HIF-1α, showing potential for promoting wound healing in preclinical diabetic models.
Conclusions:
- Targeted stabilization of HIF-1α by inhibiting its degradation pathway is a promising therapeutic strategy for diabetic wound healing.
- Existing HIF-1α stabilizers used for anemia and chronic kidney disease suggest the feasibility of this approach.
- Further research is required to validate and translate HIF-1α stabilization therapies for effective clinical application in diabetic wound management.
Related Concept Videos
01:31Diabetic Foot Ulcer
01:11Healing I: Introduction
01:22Diabetic Neuropathy
01:24Regulation of Angiogenesis and Blood Supply